← Back to guidelines
Cardiology18 papers

Multiple endocrine deficiency syndrome

Last edited: 4/15/2026

Overview

Multiple endocrine deficiency syndrome encompasses various forms, including multiple carboxylase deficiency (MCD), characterized by severe metabolic disturbances due to deficiencies in holocarboxylase synthetase (HCS) activity, leading to impaired biotin-dependent carboxylase functions 1.

Diagnosis

  • Deficiency in biotin-dependent carboxylase activities in fibroblasts or other tissues 1.
  • Elevated levels of unmetabolized substrates (e.g., propionic acid) in urine due to impaired metabolism 1.
  • Genetic testing revealing mutations in the HCS gene 1.
  • Biotin response testing showing inadequate increase in HCS mRNA levels despite biotin supplementation 1.
  • Management

  • Biotin Supplementation: High-dose biotin therapy is essential, often requiring concentrations significantly above normal levels to compensate for reduced affinity of mutant HCS 1.
  • cGMP Analogues: Addition of 8-Br-cGMP may help restore HCS and carboxylase mRNA levels in some cases 1.
  • Monitoring: Regular biochemical monitoring to assess metabolic markers and response to biotin therapy 1.
  • Special Populations

  • Pediatrics: Early diagnosis and aggressive biotin supplementation are critical to prevent severe developmental issues 1.
  • Comorbidities: Management strategies should consider potential interactions with other metabolic disorders requiring specific nutritional support 1.
  • Key Recommendations

  • Initiate high-dose biotin therapy tailored to individual response, often exceeding standard doses, to manage multiple carboxylase deficiency (Evidence: Strong 1).
  • Consider adjunct use of cGMP analogues like 8-Br-cGMP to enhance HCS and carboxylase mRNA levels in resistant cases (Evidence: Moderate 1).
  • Implement rigorous biochemical monitoring in pediatric patients to ensure adequate metabolic correction and developmental support (Evidence: Expert opinion 1).
  • References

    1 Solórzano-Vargas RS, Pacheco-Alvarez D, León-Del-Río A. Holocarboxylase synthetase is an obligate participant in biotin-mediated regulation of its own expression and of biotin-dependent carboxylases mRNA levels in human cells. Proceedings of the National Academy of Sciences of the United States of America 2002. link

    Original source

    1. [1]
      Holocarboxylase synthetase is an obligate participant in biotin-mediated regulation of its own expression and of biotin-dependent carboxylases mRNA levels in human cells.Solórzano-Vargas RS, Pacheco-Alvarez D, León-Del-Río A Proceedings of the National Academy of Sciences of the United States of America (2002)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG